Roche

Showing 15 posts of 712 posts found.

Roche’s haemophilia A drug shows meaningful bleed control in P3

December 7, 2017
Research and Development Roche, haemophilia, pharma

Roche has unveiled new Phase 3 data for its haemophilia A treatment Helimbra (emicizumab) in patients over 12 years of …

Mylan’s Ogivri becomes first and only FDA-approved Herceptin biosimilar

December 4, 2017
Sales and Marketing Biocon, Cancer, FDA, Herceptin, Mylan, Roche, biosimilar, pharma

The FDA has announced the approval of Mylan’s Ogivri (trastuzumab-dkst), the first biosimilar version of Roche’s Herceptin to be authorised …

Roche unveils strong combination treatment data in lung cancer

November 20, 2017
Research and Development, Sales and Marketing Cancer, NSCLC< lung cancer, Roche, avastin, immunotherapy, pharma, tecentriq

Roche has unveiled new Phase 3 efficacy data which showed strong findings for its immunotherapy Tecentriq (atezolizumab) in combination with …

Samsung Bioepis’ Ontruzant becomes first Herceptin biosimilar approved in Europe

November 20, 2017
Sales and Marketing EMA, Herceptin, Roche, Samsung Bioepis

Samsung Bioepis has announced that Ontruzant, the company’s biosimilar version of Roche’s Herceptin, has been awarded marketing authorisation in Europe …

Roche’s haemophillia A treatment gets nod but with black box warning

November 17, 2017
Medical Communications, Sales and Marketing Hemlibra, Roche, biotech, drugs, pharma, pharmaceutical

Roche needs its pipeline to pick up quick successes, with its big earners are looking at precipitous patent cliffs, and, …

Genentech cements relationship with Arvinas with $650m deal

November 16, 2017
Research and Development, Sales and Marketing Arvinas, Genentech, Roche, biotech, drugs, pharma, pharmaceutical

Genentech first signed a deal with Arvinas, a biotech focused on drugs within the protein degradation class, back in 2015. …

EMA recommends approval of Roche’s Ocrevus in relapsing forms of multiple sclerosis

November 13, 2017
Sales and Marketing MS, Ocrevus, Roche, multiple sclerosis, pharma

Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products …

NHS England seals access deals with big pharma for breast cancer and MS

November 9, 2017
Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …

FDA expands Roche drug indication to approve first-ever treatment for rare blood cancer

November 7, 2017
Manufacturing and Production, Sales and Marketing Cancer, Erdheim-Chester Disease, FDA, Roche, blood cancer, pharma

The FDA has announced the approval of Roche’s Zelboraf (vemurafenib) in the treatment of Erdheim-Chester Disease (ECD), expanding its already …

Roche’s Tecentriq approved for funding in UK in bladder cancer

November 1, 2017
Research and Development, Sales and Marketing Roche, biotech, drugs, pharma, pharmaceutical

In a rare spot of good news for Tecentriq (atezolizumab), after a turbulent period, Roche’s drug has been given the …

AZ tops annual R&D spend in UK, Roche is greatest pharma spender worldwide

October 24, 2017
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, GSK, GlaxoSmithKline, R&D, Roche, pwC

New findings of a report by PwC have revealed the biggest spenders in R&D worldwide as global spending hits $700 …

Roche launches Warp Drive antibiotic collaboration for $387m

October 16, 2017
Sales and Marketing Antibiotics, Roche, biotech, drugs, pharma, pharmaceutical

Roche had tentatively begun to re-enter the antibiotic space, but it has now signalled its growing intention to move in …

NICE gives final draft guidance on two key cancer drugs

October 12, 2017
Sales and Marketing Bayer, CDF, Cancer, Cancer Drugs Fund, Erivedge, NICE, Roche, Stivarga

NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the …

Roche’s 99% accurate Zika test receives FDA approval

October 9, 2017
Sales and Marketing Roche, Zika, biotech, drugs, pharma, pharmaceutical

Roche has revealed that the FDA has given approval to its cobas Zika test to determine whether a blood sample …

South Africa’s over-charging case against Aspen dissolves, remains against big names

October 6, 2017
Medical Communications, Sales and Marketing Genentech, Pfizer, Roche, aspen, biotech, drugs, pharma, pharmaceutical

South Africa’s Competition Commission has admitted that there is no case to be heard against Aspen and Equity, in regards …

The Gateway to Local Adoption Series

Latest content